Home » Topics » Musculoskeletal, BioWorld Science

Musculoskeletal, BioWorld Science
RSS

Positive phase III trial results reported by Genelabs for lupus treatment

Feb. 16, 2000

Sulfonamide-based inhibitors of TNF-alpha production synthesized at Shionogi

Feb. 14, 2000

Major European introduction for Merck's COX-2 inhibitor

Feb. 14, 2000

p38 MAPK inhibitor assessed in rat adjuvant-induced arthritis

Feb. 14, 2000

German firm launches important new drug on the domestic market

Feb. 11, 2000

Sankyo presents new inhibitors of inflammatory cytokine production

Feb. 10, 2000

New cell adhesion inhibitors designed at Celltech

Feb. 10, 2000

Idun patents new dipeptide mimetics that inhibit ICE/ced-3 cysteine proteases

Feb. 9, 2000

BASF initiates phase III clinical trials of D2E7

Feb. 9, 2000

Enbrel receives E.U. approval as treatment for rheumatoid arthritis

Feb. 8, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 26, 2026.
Brain-computer interfaces are here but long road ahead
BioWorld
The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...